Guggenheim initiated coverage of Pyxis Oncology (PYXS) with a Buy rating and $5 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Optimistic Buy Rating for Pyxis Oncology Driven by Promising MICVO Developments and Strategic Merck Collaboration
- Buy Rating for Pyxis Oncology: Promising Prospects for Micvo and Strong Financial Position
- Pyxis Oncology Reports Q2 2025 Financial Results
- Pyxis Oncology reports Q2 EPS (30c), consensus (35c)
- Pyxis Oncology Updates Phase 1 Trial Enrollment